These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

84 related items for PubMed ID: 7831353

  • 1. Prophylactic use of monophosphoryl lipid A in patients at risk for sepsis.
    Rudbach JA, Myers KR, Rechtman DJ, Ulrich JT.
    Prog Clin Biol Res; 1994; 388():107-24. PubMed ID: 7831353
    [No Abstract] [Full Text] [Related]

  • 2. Monophosphoryl lipid A as a prophylactic for sepsis and septic shock.
    Gustafson GL, Rhodes MJ, Hegel T.
    Prog Clin Biol Res; 1995; 392():567-79. PubMed ID: 8524964
    [Abstract] [Full Text] [Related]

  • 3. A rationale for the prophylactic use of monophosphoryl lipid A in sepsis and septic shock.
    Gustafson GL, Rhodes MJ.
    Biochem Biophys Res Commun; 1992 Jan 15; 182(1):269-75. PubMed ID: 1731786
    [Abstract] [Full Text] [Related]

  • 4. Drug evaluation: E-5564.
    Ondiveeran HK, Fox-Robichaud A.
    IDrugs; 2004 Jun 15; 7(6):582-90. PubMed ID: 15197664
    [Abstract] [Full Text] [Related]

  • 5. [Prevention of sepsis/septic shock in surgery of the digestive system].
    Higuero Moreno F, de la Cruz Vigo JL, de la Cruz Vigo F, de la Cruz Caro F.
    Rev Esp Enferm Apar Dig; 1981 May 15; 59(5):553-68. PubMed ID: 7291668
    [No Abstract] [Full Text] [Related]

  • 6. Antiendotoxin therapies for septic shock.
    Corriveau CC, Danner RL.
    Infect Agents Dis; 1993 Feb 15; 2(1):44-52. PubMed ID: 8162353
    [Abstract] [Full Text] [Related]

  • 7. Lipopolysaccharide-antagonizing effects of diphosphoryl lipid A from Rhodobacter sphaeroides (Rs-DPLA).
    Hofman J, Qureshi N, Takayama K, Kalin N, Manthey CL, Vogel SN, Lei MG, Morrison DC.
    Prog Clin Biol Res; 1994 Feb 15; 388():95-106. PubMed ID: 7831379
    [No Abstract] [Full Text] [Related]

  • 8. Monophosphoryl lipid A analogues with varying 3-O-substitution: synthesis and potent adjuvant activity.
    Jiang ZH, Budzynski WA, Qiu D, Yalamati D, Koganty RR.
    Carbohydr Res; 2007 May 07; 342(6):784-96. PubMed ID: 17300769
    [Abstract] [Full Text] [Related]

  • 9. Monophosphoryl lipid A protects against endotoxic shock via inhibiting neutrophil infiltration and preventing disseminated intravascular coagulation.
    Yao Z, Foster PA, Gross GJ.
    Circ Shock; 1994 Jul 07; 43(3):107-14. PubMed ID: 7850930
    [Abstract] [Full Text] [Related]

  • 10. Natural and synthetic LPS and lipid a analogs or partial structures that antagonize or induce tolerance to LPS.
    Qureshi N, Jarvis B, Takayama K, Sattar N, Hofman J, Stütz P.
    Prog Clin Biol Res; 1998 Jul 07; 397():289-300. PubMed ID: 9575570
    [No Abstract] [Full Text] [Related]

  • 11. Protection from septic shock by neutralization of macrophage migration inhibitory factor.
    Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hültner L, Heumann D, Männel D, Bucala R, Glauser MP.
    Nat Med; 2000 Feb 07; 6(2):164-70. PubMed ID: 10655104
    [Abstract] [Full Text] [Related]

  • 12. Syntheses of glucose analogues of E5564 as a highly potent anti-sepsis drug candidate.
    Shiozaki M, Doi H, Tanaka D, Shimozato T, Kurakata S.
    Bioorg Med Chem; 2006 May 01; 14(9):3011-6. PubMed ID: 16403638
    [Abstract] [Full Text] [Related]

  • 13. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines.
    Baldridge JR, Crane RT.
    Methods; 1999 Sep 01; 19(1):103-7. PubMed ID: 10525445
    [Abstract] [Full Text] [Related]

  • 14. Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo.
    Low KB, Ittensohn M, Le T, Platt J, Sodi S, Amoss M, Ash O, Carmichael E, Chakraborty A, Fischer J, Lin SL, Luo X, Miller SI, Zheng L, King I, Pawelek JM, Bermudes D.
    Nat Biotechnol; 1999 Jan 01; 17(1):37-41. PubMed ID: 9920266
    [Abstract] [Full Text] [Related]

  • 15. The safety and efficacy of the use of vasopressin in sepsis and septic shock.
    Wilson SJ, Mehta SS, Bellamy MC.
    Expert Opin Drug Saf; 2005 Nov 01; 4(6):1027-39. PubMed ID: 16255662
    [Abstract] [Full Text] [Related]

  • 16. Preservation of global cardiac function in the rabbit following protracted ischemia/reperfusion using monophosphoryl lipid A (MLA).
    Zhao L, Kirsch CC, Hagen SR, Elliott GT.
    J Mol Cell Cardiol; 1996 Jan 01; 28(1):197-208. PubMed ID: 8745227
    [Abstract] [Full Text] [Related]

  • 17. Synthesis and mitogenic activity of nonreducing-sugar subunit analogs of bacterial lipid A composed only of 3-hydroxytetradecanoic acid and its homologs.
    Ishida H, Fujishima Y, Ogawa Y, Kumazawa Y, Kiso M, Hasegawa A.
    Biosci Biotechnol Biochem; 1995 Sep 01; 59(9):1790-2. PubMed ID: 8520123
    [Abstract] [Full Text] [Related]

  • 18. The Jennerian approach to gram-negative bacillary bacteremia?
    Sanford JP.
    N Engl J Med; 1972 Aug 10; 287(6):304-5. PubMed ID: 5038959
    [No Abstract] [Full Text] [Related]

  • 19. Monophosphoryl lipid A induces delayed preconditioning against cardiac ischemia-reperfusion injury.
    Elliott GT.
    J Mol Cell Cardiol; 1998 Jan 10; 30(1):3-17. PubMed ID: 9500877
    [Abstract] [Full Text] [Related]

  • 20. Lipid A precursors protect against endotoxin challenge.
    Proctor RA.
    Adv Exp Med Biol; 1990 Jan 10; 256():641-52. PubMed ID: 2183568
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.